Finance
Diabetes-, Alzheimer-focused company reports fiscal 2005 year end financial results
Published in Obesity and Diabetes Week, October 17th, 2005
"In the last year, we achieved key clinical and company milestones with the approval of clinical trials for our lead products and the completion of a major licensing agreement for our regenerative diabetes program", said Dr. Tony Cruz, chairman and CEO of Transition.
During the fiscal year, Transition's lead regenerative diabetes product, E1-I.N.T., received clearance from the U.S. Food and Drug Administration (FDA) to commence exploratory Phase 2a clinical trials in both type 1 and type 2 diabetes....
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
More Articles from Obesity and Diabetes Week
- Diabetes Risk Factors
Characteristics of type 2 diabetes in Vietnam reported - Diabetes Risk Factors
Negative link between caffeine and diabetes actually due to weight loss - Diabetic Nephropathy
Weight loss improves renal function in obese patients with nephropathy - Diet & Nutrition
Model for improving diet counseling in primary care developed - Obesity and Diabetes
British South Asians have higher fasting glucose levels than Europeans - Anorexia Nervosa
Multiple DRD2 polymorphisms associated with anorexia nervosa - More from this issue of Obesity and Diabetes Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
